KRAS and lung cancer: The sensitivity found at baseline (48%) is slightly inferior to what has been observed in previous reports.17,18 To the best of our knowledge, this is the largest series of lung cancer patients evaluated in both tissue and plasma for the presence of KRAS mutation and dynamically analysed during treatment for the presence and quantitative change of KRAS mutation.